Navigation Links
New One-Year Data from REMICADE(R) SONIC Trial Show Sustained Efficacy Compared with Azathioprine in Treatment of Crohn's Disease
Date:6/2/2009

Crohn's disease, a chronic inflammatory disease of the gastrointestinal tract, affects approximately 500,000 Americans, including approximately 150,000 pediatric patients. The cause of Crohn's disease is not known, but the disease is associated with abnormalities of the immune system that could be triggered by a genetic predisposition or diet and other environmental factors. Symptoms of Crohn's disease can vary but often include abdominal pain and tenderness, frequent diarrhea, rectal bleeding, weight loss and fever. There is currently no cure for Crohn's disease.

About REMICADE

REMICADE was the first anti-TNF-alpha treatment to be approved in three different therapeutic areas: gastroenterology, rheumatology and dermatology. REMICADE has demonstrated broad clinical utility with indications in Crohn's disease (CD), rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), ulcerative colitis (UC), pediatric Crohn's disease (PCD) and psoriasis (PsO). The safety and efficacy of REMICADE have been well established in clinical trials over the past 16 years and through commercial experience with more than one million patients treated worldwide.

In the U.S., REMICADE is approved for the following indications:

  • Reducing signs and symptoms, inhibiting the progression of structural damage and improving physical function in patients with moderately to severely active RA, when administered in combination with methotrexate.
  • Reducing signs and symptoms in patients with active AS.
  • Reducing signs and symptoms and inducing and maintaining clinical remission in adult and pediatric patients with moderately to severely active CD who have had an inadequate response to conventional therapy.
  • Reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients wi
    '/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
2. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
4. Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
5. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
6. New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohns Disease According to First-of-its Kind Study
7. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... THOUSAND OAKS, Calif. , Jan. 15, 2014 ... and Amgen (NASDAQ: AMGN ) announced ... to jointly discover and validate new therapeutic targets ... (IBD), a chronic disorder that affects millions worldwide. ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... Inc. (Nasdaq: BMRN ) today announced that Joshua ... will present a company update at the Deutsche Bank 2010 ... 9:00 a.m. ET.   Interested parties may access ... investor section of the BioMarin website, www.BMRN.com .  A ...
... Dec. 6, 2010 SI-BONE, Inc. (San Jose, California), a ... minimally invasive surgical (MIS) device to treat the sacroiliac (SI) ... Institute, has joined its Medical Advisory Board (MAB). Dr. Rashbaum ... and Nick Shamie, along with SI-BONE founder, Mark Reiley, on ...
Cached Medicine Technology:BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 2SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 3SI-BONE Adds Texas Back Institute Founder to Its Medical Advisory Board 4
(Date:7/11/2014)... 11, 2014 Microbiology testing is a ... diagnostics industry, which is expected to pose the biggest ... sector owes its growth to the ongoing spread of ... worldwide and a major factor leading to the upsurge ... bio-terrorism, and a broader availability of immunosuppressants, among others. ...
(Date:7/11/2014)... The Europe Well Intervention Market report defines and ... and revenue forecast. The well intervention services market in Europe ... to $3.4 billion by 2018, at a CAGR of 7% ... the Europe Well Intervention Market report, to get an idea ... of the segmentation in the Europe well intervention market, and ...
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... U.S. health officials have concluded that it,s highly unlikely ... a safety mishap last month. But, the U.S. ... a moratorium on the transfer of any dangerous germs ... report issued Friday, the CDC outlined several measures the ... doesn,t occur again. Last month, as many as 75 ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
Breaking Medicine News(10 mins):Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 2Health News:World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com 3Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Europe Well Intervention Services Market is Expected to Reach $3.4 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... , RICHMOND, Calif., Aug. 18 Transcept ... to reduce operating expenses by eliminating certain staff positions following ... Products to commercialize Intermezzo ((R) )(zolpidem tartrate sublingual tablet) ... Glenn A. Oclassen, President and Chief Executive Officer commented, ...
... SAN DIEGO, Aug. 18 Aethlon Medical, ... present at today,s 14th Annual Southern California Investor Conference ... California. The conference is hosted by California Equity Research ... world-recognized life science, technology, media, and real estate/financial organizations. ...
... ... today announced that the hemostatic HemCon Patch™ and HemCon® Bandage ... with Premier Purchasing Partners L.P., the group purchasing unit of Premier ... 2011. The agreement makes HemCon dressings available at pre-negotiated terms to ...
... , INDIANAPOLIS, Aug. 18 "If commercial flying ... fire, there would be a public revolt," said Rob Schnepp, CPTC ... Fire Department in California. "The numbers aren,t going down, and this ... NFPA study reveals 87-percent of people who died in fires had ...
... ... States Health Alliance Admitted to Talent Management Organization , ... Atkins, VA (PRWEB) August 18, 2009 -- The ... world-class companies, has two new members, Qwest, headquartered in Denver, Colorado, and Mountain States ...
... , ... Group (ISG), a nationwide network of identification and card issuance sales and service experts, ... the Medical Group Management Association (MGMA). , ... Kansas City, MO (PRWEB) August 18, 2009 -- Identification Systems ...
Cached Medicine News:Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 2Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 3Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 4Health News:Transcept Announces Plans to Reduce Expenses by Decreasing Staff Following Recent Completion of Purdue U.S. License and Collaboration Agreement 5Health News:Aethlon Medical to Present at Today's Southern California Investor Conference 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 2Health News:Hemostatic HemCon Dressings Selected by the Premier Healthcare Alliance for Hemostasis Products Contract 3Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 2Health News:Cyanide Toxicity in Smoke Inhalation Victims - a Deadly but Treatable Poison 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 2Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 3Health News:Leading Communications and Healthcare Firms Join TEDS Consortium 4Health News:Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards 2Health News:Identification Systems Group Pledges Support for Standardized Patient Health Identification Cards 3
The Victory single- and dual-chamber rate-responsive pacemakers from St. Jude Medical are advanced-feature systems, designed to save valuable clinic time, maximize patient safety, and provide other t...
... the typical patient, right for the not-so-typical ... you have the ability to address the ... least expect themeven after implant. St. Jude ... to be prepared in almost any situation, ...
... Right for the typical patient, right ... Medical ICDs, you have the ability to ... when you least expect themeven after implant. ... you need to be prepared in almost ...
... Based Nursery ID and Visitor Control System. A ... hospital to compare and verify identity of those ... It helps document interactions with all visitors and ... a given child patient. It also helps to ...
Medicine Products: